Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Abstract

Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aThl composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and / or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.

Description

technical field [0001] The present invention relates to treatment with antiretroviral therapy, and more particularly to immunotherapy for HIV / AIDS. Background technique [0002] AIDS was first reported in the United States in 1981, and has since become a major epidemic worldwide. AIDS is caused by the human immunodeficiency virus, or HIV. Today, more than 30 million people living around the world are infected with the virus (Cohen, Hellmann et al. 2008). HIV works by killing or destroying cells of the body's immune system, specifically by eliminating cells expressing CD4 molecules such as CD4+ helper T lymphocytes (resulting in a reversed CD4 / CD8 T-cell ratio) and cells of the monocyte / macrophage lineage (Fauci 1996 )) immune cells and gradually destroy the body's ability to fight infection and other diseases. [0003] CD4 T cells mature into two polarized functional types, termed aTh1 and Th2 (Mosmann and Coffman 1989; Mosmann and Sad 1996). Th1 CD4+ cells are responsib...

AI Technical Summary

Problems solved by technology

Therefore, the lack of suitable donors and the toxicity of the allogeneic transplantation procedure made it impossible to convert the data from this Berlin patient to benefit the majority of HIV-infected patients